These novel Fora, in WEF-style format, will bring together corporate participants, neuroscientists and clinicians with outstanding experience in “hottest” research topics in the field of neurodegeneration to discuss the impact of newest preclinical results and cutting edge clinical findings on understanding and treatment development of neurodegenerative disorders. The objective is to exchange novel insights, challenges and solutions on the joint path forward to defining the future of Alzheimer’s and Parkinson’s therapeutics.

Each forum will be a moderated discussion with maximum 3 minutes introduction statement from each participant followed by questions from the audience. The forum is also open for journalists from different media, including lay press in and may report on progress made by the leaders in this field.

Forum Date & Title

Co-Moderators

Wednesday, March 6, 2024 | 14:30-15:30

BLOOD-BASED BIOMARKERS (BBM) – HOW DO THEY RELATE TO CSF, DIGITAL TOOLS, AND IMAGING BIOMARKERS?

Melissa Murray
Oskar Hansson

Wednesday, March 6, 2024 | 15:35-16:35

IMMUNOTHERAPIES IN AD – WHAT ARE THE PRESENT CHALLENGES AND FUTURE BENEFITS?

Robert Vassar
Susanne Hendrix

Thursday, March 7, 2024 | 17:30-18:30

NEW INSIGHTS IN THE DEVELOPMENT OF BIOMARKERS, IMAGING, AND THERAPY OF ALPHA-SYNUCLEIN, LRKK2, AND GBA PATHOLOGIES

Jamie Eberling
Walter Koroshetz

Friday, March 8, 2024 | 17:30-18:30

TRANSLATIONAL DRUG DEVELOPMENT IN AD (PHASE I-III) AND RELEVANCE FOR TREATMENT AND DISEASE MODIFICATION – WHAT COULD BE PROMISING STRATEGIES?

Jeffrey Cummings
Howard Fillit

Saturday, March 9, 2024 | 15:30-16:30

ANTI-TAU THERAPIES IN CLINICAL TRIALS – WHAT ARE THE CHALLENGES AND OPPORTUNITIES FOR A RATIONAL THERAPY?

Marc Diamond
Luc Buee

Saturday, March 9, 2024 | 17:00-18:00

THERAPY FOR AD, PD & LBD: MAJOR ETIOLOGICAL UNANSWERED QUESTIONS, MISSING TARGETS, AND FUNCTIONAL MARKERS

Manfred Windisch
Cynthia Lemere

Saturday, March 9, 2024 | 18:05 – 19:05

DRUG DEVELOPMENT & BIOMARKERS IN RARE CNS DISEASES (ALS, FTD): FROM BASICS TOWARD APPROVAL – WHAT COULD BE PROMISING STRATEGIES?

Laura Ranum
Angela Genge